This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1990 Sep 29;336(8718):820.

doi: 10.1016/0140-6736(90)93293-x.

Fludarabine monophosphate for prolymphocytic leukaemia

O P Smith, A B Mehta

PMID: 1698237
DOI: 10.1016/0140-6736(90)93293-x

Case Reports

Fludarabine monophosphate for prolymphocytic leukaemia

O P Smith et al. Lancet. 1990.

. 1990 Sep 29;336(8718):820.

doi: 10.1016/0140-6736(90)93293-x.

Authors

O P Smith, A B Mehta

PMID: 1698237
DOI: 10.1016/0140-6736(90)93293-x

No abstract available

PubMed Disclaimer

Similar articles

Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
Cervantes F, Salgado C, Montserrat E, Rozman C. Cervantes F, et al. Lancet. 1990 Nov 3;336(8723):1130. doi: 10.1016/0140-6736(90)92606-i. Lancet. 1990. PMID: 1700245 No abstract available.
Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
Leiby JM, Grever MR, Staubus AE, Neidhart JA, Malspeis L. Leiby JM, et al. J Natl Cancer Inst. 1988 May 18;80(6):447-9. doi: 10.1093/jnci/80.6.447. J Natl Cancer Inst. 1988. PMID: 2452888
Sustained response of refractory prolymphocytic leukemia to fludarabine.
Sporn JR. Sporn JR. Acta Haematol. 1991;85(4):209-11. doi: 10.1159/000204895. Acta Haematol. 1991. PMID: 1853684
Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report.
Yanai M, Maeda A, Watanabe N, Sugimoto N, Matsushita A, Nagai K, Oida T, Takahashi T. Yanai M, et al. Int J Hematol. 2004 Feb;79(2):174-7. doi: 10.1532/ijh97.03053. Int J Hematol. 2004. PMID: 15005347 Review.
Issues for the future development of fludarabine phosphate.
Cheson BD. Cheson BD. Semin Oncol. 1990 Oct;17(5 Suppl 8):71-8. Semin Oncol. 1990. PMID: 1699286 Review.

See all similar articles

Cited by

Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
Ross SR, McTavish D, Faulds D. Ross SR, et al. Drugs. 1993 May;45(5):737-59. doi: 10.2165/00003495-199345050-00009. Drugs. 1993. PMID: 7686467 Review.
Management of chronic lymphocytic leukaemia.
Kalil N, Cheson BD. Kalil N, et al. Drugs Aging. 2000 Jan;16(1):9-27. doi: 10.2165/00002512-200016010-00002. Drugs Aging. 2000. PMID: 10733261 Review.
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
Adkins JC, Peters DH, Markham A. Adkins JC, et al. Drugs. 1997 Jun;53(6):1005-37. doi: 10.2165/00003495-199753060-00007. Drugs. 1997. PMID: 9179529 Review.
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZ, Lister TA. Whelan JS, et al. Br J Cancer. 1991 Jul;64(1):120-3. doi: 10.1038/bjc.1991.253. Br J Cancer. 1991. PMID: 1713049 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database